Driven by Innovation & Growth
Our mission is to promote innovation and growth through strengthened networks; advocacy; capital investment; talent attraction, development and retention; and advancing the next generation of leaders.
Virginia's Life Science Community By the Numbers
-
3,433 Companies
Life science companies in Virginia.
-
$8B Industry
Life Science contributes $8B to Virginia's economy.
-
30, 504 People
Employed by Life Science companies in Virginia.
-
$107,281 Average Wage
Average earnings of life science workers in Virginia.
-
1,197 Clinical trials
Biopharmaceutical industry-sponsored trials in Virginia per year.
News
03/19/2026
GeneDx to Launch Genetic Testing Program with Zevra Therapeutics to Support Patients with Suspected Niemann-Pick Disease Type C
GeneDx (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced a new genetic testing program with Zevra Therapeutics, Inc. (Nasdaq: ZVRA), a commercial-stage biopharmaceutical company focused on bringing life-changing therapeutics to people living with rare diseases. The Niemann-Pick Disease type C (NPC) Sponsored Genetic Testing …
03/18/2026
Phlow Corp. Appoints Dawn Von Rohr as Chief Operating Officer to Advance Domestic Pharmaceutical Manufacturing
Phlow Corp., a leading American advanced pharmaceutical contract development and manufacturing organization (CDMO), today announced that Dawn Von Rohr has been appointed Chief Operating Officer (COO). Von Rohr will oversee Phlow’s operations, manufacturing execution, and strategic growth initiatives as the company continues expanding its advanced pharmaceutical development and manufacturing infrastructure in the United States to …
03/17/2026
W&M Undergrads expand the chemical toolbox for cancer drugs
Thanks to modern therapies, a cancer diagnosis is no longer an automatic death sentence. But many patients still suffer from unwanted side effects and limited efficacy. In a recent Bioconjugate Chemistry publication, William & Mary researchers designed an antibody-drug conjugate (ADC) with the potential to improve the potency and decrease the cost of currently approved cancer drugs. Like …
Our Premium Partners
